Nordson EFD Helps Medical Manufacturers Meet Growing Demand for COVID-19 Treatment and Diagnostic Devices
9.4.2020 15:54:00 EEST | Business Wire | Press release
Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is dedicated to helping manufacturers increase production capacity to meet the growing demand for medical devices used to treat and test for symptoms of the novel coronavirus (SARS-CoV-2).
A robotic system integrator contacted Nordson EFD on Wednesday, March 25 looking to order multiple automated dispensing systems to mass produce a small sub-assembly inside Ventec Life Systems’ unique ventilators.
Ventec’s critical care ventilators are portable and can provide front-line medical professionals with the tools they need to fight COVID-19. Ventec also manufactures VOCSN, the first and only Multi-Function Ventilator.
The sub-assembly application required bonding two components together using a UV-cure acrylic. Nordson EFD recommended its E3 automated dispensing systems and Performus X100 fluid dispensers for fast, easy setup and programming.
“Four robots left three days after the customer contacted us,” said Daniel J. Marco, application specialist at Nordson EFD. “It was great rush service from Nordson EFD. The next five robots were built and shipped the following week.”
Other high-priority applications include jetting medical reagents onto diagnostic test strips and bonding the housing of test cards for COVID-19 test kits. Nordson EFD recommended the PICO Pµlse jetting system for these applications due to its fast dispensing speed and unparalleled precision. Some systems were shipped on the day they were ordered.
Nordson EFD is dedicated to helping manufacturers meet the growing demand for medical devices required to help people during this pandemic. Backed by more than 50 years of fluid dispensing expertise and the right technology to provide remote support, Nordson EFD application and technical specialists are well-equipped to solve whatever dispensing need is at hand.
For more information, visit Nordson EFD on the web at nordsonefd.com, linkedin.com/company/nordson-efd, email at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.
About Nordson EFD
Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, Nordson EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.
About Nordson Corporation
Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005453/en/
Contact information
Natalie Tomasso
Marketing Communications Specialist
+1-401-431-7173 (USA)
natalie.tomasso@nordsonefd.com
For more information contact:
Nordson EFD
Global
Natalie Tomasso
+1-401-431-7173; natalie.tomasso@nordsonefd.com
Europe
+44 (0) 1582 666334; infoefd.europe@nordsonefd.com
China
+86 (21) 3866 9006; china@nordsonefd.com
Japan
+81 (03) 5762 2760; japan@nordsonefd.com
Korea
+82 (31) 7368321; korea@nordsonefd.com
SEAsia
+65 6796 9522; sin-mal@nordsonefd.com
India
+91 80 4021 3600; india@nordsonefd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 13:45:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time building and updating planograms and more time acting on opportunities. With greater automation, retailers can improve productivi
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De
Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 13:24:00 EEST | Press release
Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001283179/en/ Forum panel and speakers at the Abu Dhabi Future Health Summit As health systems respond to the growing burden of chronic disease and the need to help people live longer in good health, the ability to identify changing health risks and act sooner is becoming increasingly important. Hosted by Future Health – A Global Initiative by Abu Dhabi and the Department of Health – Abu Dhabi, the Future Health Summit will be held under the theme 'To Sense is to Predict', exploring the global shift from reactive m
Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 23:30:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom